Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST.
Imatinib administration in two patients with liver metastases from GIST and severe jaundice / T. De Pas, R. Danesi, C. Catania, G. Curigliano, F. de Braud. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 89:8(2003), pp. 1403-1404.
Imatinib administration in two patients with liver metastases from GIST and severe jaundice
G. Curigliano;F. de Braud
2003
Abstract
Imatinib is the only effective and approved systemic therapy for the treatment of patients with advanced gastrointestinal stromal tumours (GISTs). Although metastases from GISTs most commonly involve the liver, yielding hyperbilirubinaemia, very few data on imatinib administration in subjects with jaundice are available. We provide evidence that imatinib tolerability was not adversely affected by jaundice in two patients with advanced GIST.File | Dimensione | Formato | |
---|---|---|---|
6601282.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
82.65 kB
Formato
Adobe PDF
|
82.65 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.